InflaRx N.V. IFRX
InflaRx N.V. (Nasdaq: IFRX) is an immunology/inflammation drug developer. Its lead program, izicopan (oral C5aR inhibitor), is in Phase 2 for ANCA-associated vasculitis (AAV) and other complement-mediated renal disease; HS and CSU Phase 2a completed. Its next catalyst on record is izicopan: Data from a pharmacokinetic bridging study of izicopan in China are expected in the first half of 2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: izicopan — Data from a pharmacokinetic bridging study of izicopan in China are expected in the first half of 2027. (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vilobelimab (GOHIBIC; US EUA, EU authorization under exceptional circumstances) | SARS-CoV-2-induced ARDS / critically ill COVID-19 | antibody | Phase 3 |
| vilobelimab (anti-C5a mAb) ARDS platform study (BARDA-funded) | acute respiratory distress syndrome | antibody | Phase 2 |
| izicopan Phase 2a (completed) | hidradenitis suppurativa; chronic spontaneous urticaria | small molecule | Phase 2 |
| izicopan AAV Phase 2 (planned) | ANCA-associated vasculitis | small molecule | Phase 2 |
| vilobelimab / anti-C5a for AAV (Phase 2 IXCHANGE/IXPLORE completed) | ANCA-associated vasculitis | antibody | Phase 2 |
| IFX002 (next-generation anti-C5a antibody) | chronic inflammatory diseases | antibody | Pre-clinical |
Recent results and decisions
- Nov 3, 2026started InflaRx plans to initiate a randomized, placebo-controlled Phase 2 trial of izicopan in AAV patients with renal vasculitis in early 2027.
InflaRx expects trial site initiation to begin in early 2027 for a randomized, placebo-controlled Phase 2 study in patients with AAV with renal involvement (i.e., renal vasculitis).
Filing - Oct 22, 2026positive Izicopan demonstrated significant renal protection in pre-clinical hamster models of kidney injury.
In both settings, oral izicopan significantly attenuated renal injury compared to vehicle-treated controls.
Filing - Oct 21, 2026positive Pre-clinical data showed izicopan significantly attenuated renal injury in hamster models of acute kidney injury (IRI) and progressive renal injury (UUO).
In both settings, oral izicopan significantly attenuated renal injury compared to vehicle-treated controls.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.